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Abstract: The cytochrome P450 (CYP) family 1A enzymes, CYP1A1 and CYP1A2, are two of the
most important enzymes implicated in the metabolism of endogenous and exogenous compounds
through oxidation. These enzymes are also known to metabolize environmental procarcinogens into
carcinogenic species, leading to the advent of several types of cancer. The development of selective
inhibitors for these P450 enzymes, mitigating procarcinogenic oxidative effects, has been the focus
of many studies in recent years. CYP1A1 is mainly found in extrahepatic tissues while CYP1A2
is the major CYP enzyme in human liver. Many molecules have been found to be metabolized by
both of these enzymes, with varying rates and/or positions of oxidation. A complete understanding
of the factors that govern the specificity and potency for the two CYP 1A enzymes is critical to
the development of effective inhibitors. Computational molecular modeling tools have been used
by several research groups to decipher the specificity and potency factors of the CYP1A1 and
CYP1A2 substrates. In this review, we perform a thorough analysis of the computational studies that
are ligand-based and protein-ligand complex-based to catalog the various factors that govern the
specificity/potency toward these two enzymes.
Keywords: cytochrome; P450 1A1; P450 1A2; docking; quantitative structure activity studies (QSAR);
molecular modeling; dynamics; active site
1. Introduction
Research on cytochrome P450 enzymes has evolved over the years from the initial in-vitro
substrate metabolism studies to the studies on the metabolism of drugs and the role of these enzymes
in various diseases including cancer. The Human Genome Project revealed that there are 57 human
P450 (CYP) genes and 58 pseudogenes [1]. CYP enzymes are found in all living organisms and catalyze
the mono-oxygenation of many different substrates. Mammalian cytochrome P450 enzymes can
oxidize both endogenous compounds and xenobiotics, thereby playing critical roles in cholesterol
and hormone synthesis, metabolism of endogenous compounds such as vitamin D, drug deactivation,
and xenobiotics detoxification. The CYP1 family of P450 enzymes comprises of three members 1A1,
1A2, and 1B1. CYP1A1 and CYP1A2 are closely related with the CYP1A gene cluster that is mapped
to chromosome 15q24.1, with head-to-head orientation, sharing a 23 kb bi-directional promoter and
a common 5′-flanking region [2]. CYP1A1 gene spans 5.8 kb and CYP1A2 gene spans 7.8 kb with seven
exons and six introns [3,4]. CYP1A2 is the highly expressed cytochrome enzyme in the human liver
(~13–15%) [5], while CYP1A1 expression levels are low in the liver (<0.7%), and it is mostly found in
extrahepatic tissues [6,7].
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2. CYP1A Substrates
The span of enzymatic activities of CYP1A1 and CYP1A2 vastly overlaps with hydroxylations
and oxidations of aromatic compounds including polycyclic aromatic hydrocarbons. Arachidonic
acid and eicosapentoic acid, involved in synthesis of inflammation factors and hormones such as
melatonin and 17β-estradiol, are endogenous substrates for CYP1A1 [8–10]. CYP1A1-dependent
metabolic activation of procarcinogens into carcinogens via epoxides is well established in cancer
initiation [11,12]. Other CYP1A1 exogenous substrates include heterocyclic aromatic amines of
industrial origin or those that are found in burnt food such as meat, fuel combustion products,
and tobacco products [12,13]. Some of the endogenous substrates that are metabolized by both
CYP1A1 and CYP1A2 include melatonin, 6-hydroxylate melatonin, and arachidonic acid, etc. Several
other endogenous substrates are metabolized by CYP1A2 including estradiol, estrone, bilirubin,
and uroporphyrinogen, etc. CYP1A2 metabolizes numerous natural products that result in toxic
products such as transformation of methyleugenol to 1′-hydroxymethyleugenol, estragole to reactive
metabolites, oxidation of nephrotoxins, and aristolochic acids [14–16]. CYP1A2 plays an important
role in the metabolism of several clinical drugs including analgesics, antipyretics, antipsychotics,
antidepressants, anti-inflammatory, and cardiovascular drugs [17–20].
3. Structure and Catalytic Cycle
The overall fold structure of all of the cytochrome P450 enzymes is identical, even though the
sequence identify across the entire superfamily is less than 20%. The three-dimensional structure
consists of 12 α-helices, A-L, that form the bulk of the protein, and four β-sheets. The heme cofactor is
housed within the L-helix and the highly conserved I-helix that is perpendicular to the F/G segment
comprising of the F-helix, F/G-loop and the G-helix. The heme Fe atom is bound to the sulfur atom of
the Cys in the adjacent loop that has the highly conserved sequence FxxGx(HRK)xCxG. Substrate access
and specificity is governed by B-C and F-G helices. The sequence identity between the two CYP1A1
(512 aa) and CYP1A2 (515 aa) enzymes is 71%. The X-ray crystal structure of CYP1A2 (2HI4) was
reported by Johnson’s group in 2006 [21] and the CYP1A1 X-ray structure (PDB code: 4I8V) was
reported by Scott’s group in 2013 [22]. The two CYP1A enzymes exhibit an overall similarity in
their three-dimensional structures (Figure 1). However, there are some key structural differences as
exemplified by their X-ray crystal structures (PDB codes 4I8V and 2HI4 for CYP1A1 and CYP1A2,
respectively). Scott et al. reported the structural variations between the two enzymes. CYP1A1 and
CYP1A2 differ from other cytochrome P450 enzymes in the rigidity of the H/I loop, the break in the
F helix, and the secondary structure of the β4 region. The H/I loop of CYP1A2 contains two short
β-strands made of two residues each, that are not seen in the crystal structure of CYP1A1. The most
important structural difference is seen in the F helices of CYP1A1 and CYP1A2. There is a three-residue
break in the middle of the F helix in the CYP1A2 structure and this break is extended to five residues
in the CYP1A1 structure. The F helix plays an important role in substrate access/egress and is also
involved in the binding site regioselectivity and stereoselectivity preferences. The secondary structure
adopted by the β4 system of two strands is absent in the structures of CYP1A1 and CYP1A2. The turn
of the β4 loop that lines the binding cavity is known to exhibit ligand interactions and provide ligand
access. In addition to these differences, the B’ helix exhibits minor differences in hydrogen bonding
pattern between the CYP1A1 and CYP1A2. The notable differences in the features that define the
substrate access/regress paths and the substrate-binding cavity indicate that the CYP1A enzymes may
indeed allow for substrate specificity in binding, orientation and the point of oxidation.
The catalytic cycle of the cytochrome P450 enzymes can be commonly defined by the protein heme
iron—oxygen roles through the cycle. The resting state of the enzyme involves a low-spin ferric enzyme
with a water molecule coordinated as the sixth ligand of the heme iron atom. The binding of a substrate
to the enzyme sometimes changes it to a high-spin ferric state for the enzyme-substrate complex. The
next step in the cycle is the oxygen binding to the heme iron to form an oxy-iron-P450 complex which
is a stable intermediate. The next sequence of steps occurs rapidly to form unstable intermediates:
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reduction of the oxy-iron-P450 complex to form the peroxo-ferric-P450 complex, protonation of the
distal oxygen to form the hydroperoxo-iron-P450 complex, and a second protonation of the same
oxygen followed by heterolytic cleavage of the bond between the two oxygen atoms leading to the
formation of a reactive high-valent iron-oxo-P450 complex which is generally called ‘Compound 1’.
Compound 1 then abstracts a hydrogen from the substrate with subsequent radical recombination to
produce the oxidized substrate that is egressed. The resting state of the P450 enzymes is regenerated
by the binding of a water molecule to the heme iron atom (Figure 2).
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Figure 1. (A) The X-ray crystal structures of CYP1A1 (4I8V.pdb, pink) and CYP1A2 (2HI4.pdb, green)
are superposed as ribbon model. Atoms are shown as ball and stick models. Heme is colored white
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of the heme bound to Cys sulfur atom as the fifth ligand and the water molecule as the sixth ligand.
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is anchored to the enzyme through the entire cycle by its covalent linkage to the sulfur atom of the
Cys residue.
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4. Inhibition of CYP1A Enzymes
The role of CYP1A1 and CYP1A2 in metabolizing procarcinogens to carcinogens leading to
mutagenesis and tumorigenesis has been well documented [13,23–27]. Targeting these enzymes for
inhibition can help in cancer prevention by inhibiting the conversion of environmental procarcinogens
to their carcinogenic forms, inhibiting the formation of carcinogenic hormone derivatives from
hormonal precursors, and inhibiting the metabolic inactivation of several therapeutic agents including
anticancer drugs [28]. Several small natural compounds are also inhibitors of CYP1A1 and
CYP1A2. The quinazolinecarboline alkaloids- evodiamine, dehydroevodiamine and rutaecarpine from
Evodia rutaecarpa, have been traditionally used for the treatment of hypertension, and gastrointestinal
disorders in Chinese medicine [29]. Naturally occurring flavonoids are well known for their inhibition
of toxicological processes and drug disposition. These natural inhibitors of CYP1A1 and CYP1A2
could have an important role in cancer prevention by reducing the metabolism of procarcinogens
by these enzymes. Thus, they have been prescribed as essential dietary components by regulating
agencies worldwide.
The inhibitors of P450 enzymes fall into two main categories- direct competitive inhibitors
and time-dependent inhibitors. Competitive inhibitors are capable of accessing the active site and
reversibly binding to the active site. These kinds of molecules need to have a much higher affinity to
the target enzyme than the natural substrates. Time-dependent inhibitors are also capable of accessing
the active site and binding to the active site [30,31]. When these inhibitors are initially incubated
with the enzyme before the addition of the substrate, an increase in inhibition is observed, which
is a kinetic phenomenon. This category can be further defined by its subset of mechanism-based
inactivation wherein the bound inhibitor is oxidized by the enzyme to a highly reactive intermediate
that subsequently binds to a reactive amino acid in its proximity. This process permanently changes
the enzyme active site, resulting in the inactivation of the enzyme. This process is both time- and
cofactor-dependent. Several classes of inhibitors have been found that act as direct competitive
inhibitors or time-dependent inhibitors.
5. Substrate Binding Site Characteristics
The substrate binding cavity is defined by the I, F, G, C and B’ helices, the loop between the K helix
and β1–4 sheets and the residues at the turn of the β4 region. The X-ray crystal structures of the CYP1A1
and CYP1A2 demonstrate several similarities between the two enzymes’ active sites (Figure 3).
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Figure 3. The molecular surface representation of the active site pocket of the (A) CYP1A1 and (B) 
CYP1A2 enzymes colored by lipophilicity where the pink region depicts hydrophilic region of the 
pocket and the green region depicts the lipophilic region of the pocket. The heme residue is 
represented as white stick model, the ligand (α-naphthoflavone) is shown as yellow stick model, and 
the enzyme residues are shown as cyan stick models. 
Figure 3. The molecular surface representation of the active site pocket of the (A) CYP1A1 and (B)
CYP1A2 enzymes colored by lipophilicity where the pink region depicts hydrophilic region of the
pocket and the green region depicts the lipophilic region of the pocket. The heme residue is represented
as white stick model, the ligand (α-naphthoflavone) is shown as yellow stick model, and the enzyme
residues are shown as cyan stick models.
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A comparative protein structural analysis between the X-ray crystal structures of CYP1A1 and
CYP1A2 has been performed by Kesharwani et al. [32,33]. They describe several differences in the
six identified substrate recognition sites between the two CYP1A enzymes. They have also identified the
residues in CYP1A1 and CYP1A2 showing higher B-factor values than the average B-factor. They are-
Asn221, Leu254, Asp320 and Lys499 in the F, G, I and L helices of CYP1A1, and Thr118, Asp320, Thr321,
Leu382 and Ile386 in the B’ and I helices and the loop connecting K helix to β2 sheet of CYP1A2. Several
identical residues are aligned in identical orientations in the active site spaces such as the Ile-115/117,
Phe-123/125, Phe-224/226, Thr-321, Asp-320, Ile-386, Leu-496/497, Asn-255/257, and Thr-497/498
in CYP1A1/CYP1A2. The two non-conserved residues with similar properties in the active sites of
CYP1A1/CYP1A2 are the Ser116/Thr118 and the Ser122/Thr124. The three non-conserved residues with
different properties in the active sites of CYP1A1/CYP1A2 are the Asn222/Thr223, the Leu312/Asn312,
and the Val382/Leu382. The B-factor analysis indicated that the non-conserved residues and the residues
with higher B-factors demonstrated greater mobility and flexibility.
6. Ligand-Based Studies on Isoform Selectivity
While the X-ray crystal structures provide a detailed map of the substrate recognition sites and
the active sites, the wide range of the substrates and inhibitors for the two enzymes with varied shapes
and sizes indicate the plasticity of the active sites defined by the flexibility and movement of the
helices surrounding the active sites. The shapes of the active sites are defined by the F and I helices
in the two enzymes CYP1A1 and CYP1A2, forming a flat surface between these helices, that clearly
indicate the preference for planar molecules. The selective inhibition of either CYP1A1 or CYP1A2 has
been a challenge due to the large number of substrates with varied structures that are metabolized by
both enzymes.
To study the nature of the active site cavities in these enzymes, a series of planar molecules,
naphthoflavones and pyranoflavones, were synthesized by our group. A meta-analysis of these
molecules was performed to study the inhibitor selectivity toward CYP1A1 and CYP1A2 (Figure 4).
In light of the variations in the inhibitory data from different methods of determination, a selectivity
ratio which is a measure of the ratio of the IC50 values of the inhibitors for CYP1A1 and CYP1A2 was
used to define two groups of inhibitors (IC50 for CYP1A1/IC50 for CYP1A2 ratios <0.2—group1 and
>5—group 2) for the comparative meta-analysis (Figure 5).
Molecules 2017, 22, 1143  5 of 18 
 
A comparative protein structural analysis between the X-ray crystal structures of CYP1A1 and 
CYP1A2 has been performed by Kesharwani et al. [32,33]. They describe several differences in the six 
identified substrate recognition sites between the two CYP1A enzymes. They have also identified the 
residues in CYP1A1 and CYP1A2 showing higher B-factor values than the average B-factor. They are- 
Asn221, Leu254, Asp320 and Lys499 in the F, G, I and L helices of CYP1A1, and Thr118, Asp320, 
Thr321, Leu382 and Ile386 in the B’ and I helices and the loop connecting K helix to β2 sheet of 
CYP1A2. Several identical residues are aligned in identical orientations in the active site spaces such 
as the Ile-115/117, Phe-123/125, Phe-224/226, Thr-321, Asp-320, Ile-386, Leu-496/497, Asn-255/257, and 
Thr-497/498 in CYP1A1/CYP1A2. The two non-conserved residues with similar properties in the 
active sites of CYP1A1/CYP1A2 are the Ser116/Thr118 and the Se 122/Thr124. Th  three non-
conserved residues with different properties in the active site  of CYP1A1/CYP1A2 are the 
Asn222/Thr 23, the Leu312/Asn312, and the Val382/Leu382. The B-facto  analysis indicated that the 
non-conserved residues a d the residues with higher B-factors demonstrated greater mobility and 
flexibility.  
6. Ligand-Based Studies on Isoform Selectivity 
While the X-ray crystal structures provide a detailed map of the substrate recognition sites and 
the active sites, the wide range of the substrates and inhibitors for the two enzymes with varied 
shapes and sizes indicate the plasticity of the active sites defined by the flexibility and movement of 
the helices surrounding the active sites. The shapes of the active sites are defined by the F and I helices 
in the two enzymes CYP1A1 and CYP1A2, forming a flat surface between these helices, that clearly 
indicate the preference for planar molecules. The selective inhibition of either CYP1A1 or CYP1A2 
has been a challenge due to the large number of substrates with varied structures that are metabolized 
by both enzymes.  
To study the nature of the active site cavities in these enzymes, a series of planar molecules, 
naphthoflavones and pyranoflavones, were synthesized by our group. A meta-analysis of these 
molecules was performed to study the inhibitor selectivity toward CYP1A1 and CYP1A2 (Figure 4). 
In light of the variations in the inhibitory data from different methods of determination, a selectivity 
ratio which is a measure of the ratio of the IC  values of the inhibitors for CYP1A1 and CYP1A2 was 
used to define two groups of inhibitors (IC50 for P1 1/IC50 for CYP1A2 ratios <0.2—group1 and 





Molecules 2017, 22, 1143 6 of 19
Molecules 2017, 22, 1143  6 of 18 
 
Figure 4. Cont. 
 
Figure 4. Structures and CYP1A1 & CYP1A2 inhibition data for (A) & (C) linear planar molecules and 
(B) & (D) triangular planar molecules [(A) and (B) reprinted from reference 34 with permission ]. 
 
Figure 5. Alignment images of group 1 and group 2 inhibitors. (A) and (C) Group 1 represents 
selective P450 1A1 inhibitors. (B) and (D) Group 2 represents selective P450 1A2 inhibitors. [Figure 
was reprinted from reference 34 with permission]. 
Structural alignments between the two groups of inhibitors showed that selective CYP1A1 
inhibitors have a long strip shape with an average length of 12.3 Å , and average width of 4.6 Å , 
showing a narrow and long cavity for CYP1A1. The alignment of the groups of selective CYP1A2 
inhibitors form a triangular shape with side lengths of 9.3 Å , 8.7 Å , and 7.2 Å , that are indicative of a 
narrow compact triangular cavity for CYP1A2 [34]. The impact of the ligand shape on the enzyme 
specificity for CYP1A1 and CYP1A2 was confirmed by the study of the derivatives of long planar 
molecules such as anthracene, phenazines, phenothiazines, acridines, and anthracene-9,10-diones, all 
showing greater inhibition potency for CYP1A1 than CYP1A2 [34–37] (Figure 4). On the other hand, 
triangular shaped molecules such as phenanthrenes and carbazoles clearly show greatly increased 
potency toward CYP1A2 compared to CYP1A1 [34,36,37] (Figure 4). 
Several structure-activity relationship studies such as CoMFA, SAR, 3D-QSAR have been 
undertaken by researchers to understand the ligand interactions with the residues in the protein 
active site. The goals of such studies included virtual screening, prediction of the site of metabolism, 
and prediction of the potency/selectivity of inhibition of the CYP enzymes. Our group has recently 
Figure 4. Structures and CYP1A1 & CYP1A2 inhibition data for (A) & (C) linear planar molecules and
(B) & (D) triangular planar molecules [(A) and (B) reprinted from reference 34 with permission ].
Molecules 2017, 22, 1143  6 of 18 
 
Figure 4. Cont. 
 
Figure 4. Structures and CYP1A1 & CYP1 2 i i iti  t  for (A) & (C) linear planar molecules and 
(B) & (D) triangular planar molecules [(A) and (B) re ri te  fr  reference 34 with permission ]. 
 
Figure 5. Alignment images of group 1 and group 2 inhibitors. (A) and (C) Group 1 represents 
selective P450 1A1 inhibitors. (B) and (D) Group 2 represents selective P450 1A2 inhibitors. [Figure 
was reprinted from reference 34 with permission]. 
Structural alignments between the two groups of inhibitors showed that selective CYP1A1 
inhibitors have a long strip shape with an average length of 12.3 Å , and average width of 4.6 Å , 
showing a narrow and long cavity for CYP1A1. The alignment of the groups of selective CYP1A2 
inhibitors form a triangular shape with side lengths of 9.3 Å , 8.7 Å , and 7.2 Å , that are indicative of a 
narrow compact triangular cavity for CYP1A2 [34]. The impact of the ligand shape on the enzyme 
specificity for CYP1A1 and CYP1A2 was confirmed by the study of the derivatives of long planar 
molecules such as anthracene, phenazines, phenothiazines, acridines, and anthracene-9,10-diones, all 
showing greater inhibition potency for CYP1A1 than CYP1A2 [34–37] (Figure 4). On the other hand, 
triangular shaped molecules such as phenanthrenes and carbazoles clearly show greatly increased 
potency toward CYP1A2 compared to CYP1A1 [34,36,37] (Figure 4). 
Several structure-activity relationship studies such as CoMFA, SAR, 3D-QSAR have been 
undertaken by researchers to understand the ligand interactions with the residues in the protein 
active site. The goals of such studies included virtual screening, prediction of the site of metabolism, 
and prediction of the potency/selectivity of inhibition of the CYP enzymes. Our group has recently 
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P450 1A1 inhibitors. (B) and (D) Group 2 represents selectiv P450 1A2 inhibitors. [Figure was reprinted
from ref renc 34 with p mission].
Structural alignments bet ps of inhibitors showed that s lective CYP A1
inhib tors have a long strip sha erage length of 12.3 Å, and average width of 4.6 Å,
showing a narrow and long cavity for . he alignment of the groups of s lective CYP1A2
inhibitors form a triangular shape ith side lengths of 9.3 Å, 8.7 Å, and 7.2 Å, that are indicative of
a narro co pact triangular cavity for CYP1A2 [34]. The impact of the ligand shape on the enzyme
specificity for CYP1A1 and CYP1A2 was confirmed by the study of the derivatives of long planar
molecules such as anthracene, phenazines, phenothiazines, acridines, and anthracene-9,10-diones,
all showing greater inhibition potency for CYP1A1 than CYP1A2 [34–37] (Figure 4). On the other hand,
triangular shaped molecules such as phenanthrenes and carbazoles clearly show greatly increased
potency tow rd CYP1A2 ompared to CYP1A1 [34,36,37] (Figure 4).
Several structure-activity relationship studies such s CoMFA, SAR, 3D-QSAR have been
undertaken by r searcher to understand the ligand inte actions with the residu s n the protein active
site. The goals of such studies included virtual screening, prediction of the site of met bolism, and
prediction of the potency/selectivity of inhibition of the CYP enzymes. Our group has recently published
extensive reviews on these studies [35,38]. Two types of QSAR models have been employed to study the
P450 substrates. The first one is a global QSAR model that is used to predict the ADMET (absorption,
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distribution, metabolism, elimination and toxicity), which is not very useful in terms of understanding
the active site properties and prediction of potency/selectivity. The second type is the detailed QSAR
for specific P450 enzymes of smaller sets of molecules that are structurally related. These models are
very robust and give a more precise representation of the active site interactions and structural features
that impart potency and specificity. Several descriptors including electrostatic, hydrophobic, hydrogen
bond acceptor/donor, steric, and desolvation free energy have been studied using quantum/molecular
mechanical calculations. Many of these models have been verified by docking studies.
QSAR studies on CYP1A1 substrates have been performed by several research groups on
polyaromatic hydrocarbons, flavonoids, benzoxazoles, benzothiazoles, and several other inhibitors
of CYP1A1 [39–46]. These studies have shown that the properties that impact the binding of the
substrates are the linear planarity of the molecules, the HOMO energy, π-π stacking with the Phe
residues, optimally placed acceptor and donor substituents that can interact with the polar residues in
the active site, and desolvation (ClogP).
QSAR analysis of CYP1A2 substrates and inhibitors has been widely studied by many researchers
as well [39,45–51]. Chemometric tools that employ stepwise multiple linear regression, genetic
function approximation, and genetic partial least squares have been used for small sets of structurally
similar molecules. Machine learning techniques such as associative neural networks, kappa nearest
neighbor random tree, random forest, and decision tree methods have been used to develop predictive
models for large sets of molecules with varied structures. Planarity of the molecule (area/depth2
ratio) and molecular mass were found to be the critical requisites for molecules to be CYP1A2
substrates/inhibitors.
7. Protein-Based Studies Using Molecular Docking and Molecular Dynamics
The extensive ongoing research worldwide to better understand the oxidation of exogenous/
endogenous substrates by CYP1A enzymes, and the efforts for the development of CYP1A inhibitors
have led to the wide use of docking studies and molecular dynamic studies on the enzymes. To better
understand the interactions of the substrate with the enzyme and the specificity of ligands for either
CYP1A1 or CYP1A2, docking studies using computational molecular modeling tools has been the go-to
method. The docked substrate-enzyme features that have been analyzed are the binding free energies,
the interactions between the substrate and the residues lining the active site, and the distance between
the heme iron and the substrate reacting group. The docking studies described on CYP1A enzymes
employed different software including AutoDock, Surflex dock from Tripos SYBYL, the docking
module from Molecular Operating Environment (MOE), etc. The binding scores reflect the binding free
energy obtained using a functional form of various terms that describe different interactions including
hydrogen bond interactions, hydrophobic interactions, ionic interactions, metal ligation, hydrophobic
and polar/aromatic interactions, entropy, desolvations, etc. The value of the binding free energy
obtained will depend upon the scoring method employed. The docking studies are validated if there
is good correlation of the bioactivity to the docking score. Furthermore, the docking studies produce
several binding poses. Some researchers employ 2 or more docking methods and find a consensus
binding mode which is then used for scoring to obtain the binding free energy. Docking studies on CYP
enzymes have used the optimal distance between the atom of oxidation on the ligand to the heme iron
atom (4.0 Å to 7.5 Å) as the chief criteria for determining the best binding mode of the ligand.
Oxidation of aromatic hydrocarbons and polyaromatic hydrocarbons (PAHs) found in the
environmental pollutants to carcinogens by cytochrome P450 enzymes is a major cause of concern.
Docking and QSAR studies were performed by Gonzalez et al. on 37 representative compounds that
consisted of PAHs, PAH diols, and heterocyclic aromatic compounds onto CYP1A1 [41]. They used
a homology model built using SWISS-MODEL for CYP1A1 as the X-ray crystal structure of CYP1A1
was not reported at the time of this study. It was observed that hydrophobic interactions played an
important role in ligand binding. The residues involved were Phe123, Phe224 and Phe258. It was also
seen that the ligand orientations were favoring π-π interactions in an edge-to-face manner with Phe123,
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and offset stacked manner with Phe224 and Phe258. Heterocyclic aromatic carbon PAH diols exhibited
binding orientations similar to those of PAHs with π-π interactions and hydrophobic interactions with
the Phe residues and with the polar groups forming hydrogen bond interactions with polar amino
acids in the active site such as Asn221, Ser122, or Asp320, respectively.
Arylacetylenes were developed by our group as time-dependent inhibitors of CYP1A1 and
CYP1A2 [52]. These molecules are members of the PAHs with an acetylenic moiety as a substituent,
which imparts the time-dependent inhibition via a reactive ketene intermediate. These molecules
did not possess any polar groups and were incapable of hydrogen bonding interactions with the
active site polar residues. All of the arylaceylenes made the critical edge-to-face and offset stacked π-π
interactions with the Phe residues in the active site of the CYP1A enzyme (Figure 6A,B). For CYP1A1,
the distance between the heme iron atom and the triple bond of the acetylene moiety determined the
potency of the inhibitors (Figure 6C). In the case of CYP1A2, the π-π stacking interactions were found
to be the most important determinants of the inhibition potency (Figure 6D).
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Figure 6. Docking studies showing the π-π interactions between the arylacetylenes and the enzymes
(A) CYP1A1 and (B) CYP1A2. The docking studies also showed (C) the direct relationship between
the inhibitory activity and the heme-acetylene moiety distance for CYP1A1 and (D) the relationship
between the inhibitory activity and distance between centroids of aromatic rings of Phe residues and
arylacetylenes for CYP1A2. [(A) and (B) reprinted from reference 52 with permission].
Benzoxazole and benzothiazole anticancer agents are known to inhibit CYP1A1. Surflex docking
studies and CoMFA analysis f 48 derivatives of benzoxazoles and benzothiazoles were performed by
Pan et al. [53] o t e homology model of CYP1A1. Arg106 and Ile386 of CYP1A1 played important
roles in forming hydrogen bonds with the oxygen atoms of these molecules. They concluded that
the hydrogen bond interactions of these molecules with Ile386 are critical in determining the potency
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of inhibition for CYP1A1 (Figure 7). The binding free energy, CScores and the antitumor activity
(pGI50) were compared for the docked structures of all 48 benzoxazole and benzothiazole derivatives.
The pGI50 values ranged from 4.37 to 8.68, and the CScores varied from 4.47 to 7.54. The free energy of
binding ranged from −6.07 kcal/mol to −10.38 kcal/mol. The authors found that the activity of the
compounds corresponded well with the CScores.
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(a) nd 4-(benzo[d]thiazol-2-yl)benz e-1,2-diol (b) docked into the binding site of CYP1A1. Important
residues re shown as sticks.
Flavonoids are natural products that have antioxidative and antimutagenic properties thereby
preventing several debilitating diseases including cancer, heart disease, and bone loss. Flavonoids
are well known to inhibit several cytochrome P450 enzymes such as P450s 1A1, 1A2, 1B1, 2C9 and
3A4. Docking and QSAR studies were performed for several PAHs and flavonoids on the X-ray
crystal structure of CYP1A2 and the homology model of CYP1A1 by Shimada et al. [54]. Several of
docked flavones had hydroxyl groups at various positions of the aromatic rings. The ligand-interaction
energies varied between −9.5 and 255 (U values, kcal/mol). A clear correlation between the U values
and the IC50 values for inhibition of CYP1A1, CYP1A2 and CYP1B1 was not found. The binding
orientation of these flavonoids differed between CYP1A1 and CYP1A2. In the case of strong inhibitors,
the flavonoid B-rings docked close to the heme iron center of CYP1A2, and the π-π stacking of the
favora ly oriented fl vonoid hydroxyl group with Phe226 was evidenced. Weak inhibitors favored an
orientation that was different from that of the tr g inhibitors for CYP1A2, in which the π-π stacking
with Phe226 seen in strong inhibitors was absent for weak inhibitors. In the case of CYP1A1, all of the
flavonoids docked in similar orientations in the active site. The studies indicated that the presence of
a 5,7-dihydroxyl group in the A ring and a 3-hydroxyl group in the C ring of the flavone increased the
inhibition potency for these enzymes. These studies also showed that the presence of 3′,4′-dihydroxyl
group in the B-ring of the flavone could increase the inhibition potency.
Citrus fruits such as oranges, mandarins, and grapefruits are rich in flavonoids and coumarins that
potently inhibit several CYP enzymes including CYP 1A1, CYP1A2, and CYP3A4. The components of
grapefruit juice have been extensively studied for their interactions with several drugs and their role
as chemoprotective agents. Furanocoumarin monomers, bergamottin and 6′,7′-dihydroxybergamottin
(DHB) are potent inhibitors of CYP1A1 and CYP1A2 [55–57]. The flavonoid naringenin (NAR) isolated
from grapefruit juice is a potent competitive inhibitor of CYP1A1. Espinosa-Aguirre et al. have studied
the binding of DHB and NAR to human and rat forms of CYP1A1 through kinetic analysis and docking
studies [58]. Kinetic analysis revealed species-related differences in the DHB and NAR inhibition of
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CYP1A1 by type and potency. DHB exhibited competitive inhibition of CYP1A1 in both species, but
with an increased inhibition kinetics Ki for human CYP1A1 (55 µM) than for rat CYP1A1 (1.73 µM).
NAR showed species variation in type of inhibition with competitive inhibition of human CYP1A1
(Ki = 489 µM) and mixed type inhibition for rat CYP1A1 (Ki = 0.17 µM and KI = 0.39 µM). Molecular
dynamics simulations on the X-ray crystal structure of human CYP1A1 and homology model of rat
CYP1A1 showed similar catalytic site fluctuations. Four critical residues in the binding site varied
between the species- humanCYP1A1/ratCYP1A1: Ser116/Ala120, Ser122/Thr126, Asn221/Ser225,
and Leu312/Phe316, and interactions with these differing residues by DHB and NAR could account
for the differences in type and potency of inhibition. The docking scores for NAR and DHB for human
CYP1A1 were −6.65 kcal/mol and −8.85 kcal/mol. The docking score for NAR with rat CYP1A1
was lower at −5.77 kcal/mol while the docking score for DHB with rat CYP1A1 was −8.05 kcal/mol,
which is comparable to that of the human CYP1A1. The other interesting finding in these docking
studies was the presence of two potential binding sites for DHB and NAR, the primary catalytic
site and an adjacent secondary binding site below the primary site that was exposed to the solvent.
This secondary binding site was much larger than the primary catalytic site in rat CYP1A1.
Our research group developed several flavone propargyl ethers that selectively inhibit CYP1A1
and CYP1A2 compared to CYP2A6 and CYP2B1 [45]. In that study, 3′-flavone propargyl ether (3′-PF)
and 7-hydroxyflavone (7-HF) were also proved to be time-dependent inhibitors of CYP1A1. The
rate constants of 3′-PF and 7-HF for maximal inactivation at saturation (kinact) were 0.09 and 0.115
min−1, respectively, and the concentrations required to produce one-half of the maximal rates of
inactivation (KI) were 0.24 and 2.43 µM, respectively. Docking studies showed that these compounds
exhibited multiple π-π interactions with the Phe residues in the active site of both CYP1A enzymes.
For CYP1A2 enzyme, all of the compounds except for 5-hydroxyflavone were oriented in the active
site in such a way that the hydroxyl group was closest to the heme of the enzyme. Even though the
flavone propargyl ethers are longer molecules than the hydroxy flavones, their binding orientation
in the enzyme active site showed the triple bond closest to the heme center with the signature π-π
interactions with the active site Phe residues still maintained. It has been suggested that the unstable
ketene intermediate formed by the oxidation of the triple bond could react with the neighboring Arg
residue to form an amide bond, leading to the time-dependent inhibition of CYP1A1.
Coumarins are one of the classes of compounds that are known to be metabolized by several CYP
enzymes including 1A1, 1A2, 3A4, 2A6 and some from the 2B subfamily. Based on the observation that
the key metabolic site on the coumarin core structure is the 7-position, our group developed several
substituted derivatives of 7-ethynylcoumarin that exhibit selective inhibition of CYP1A1 and CYP1A2
in a time-dependent manner [59]. Two different orientations were found for these 7-ethynylcoumarin
derivatives in the CYP1A2 active site. 3-Phenyl substituted derivatives docked in such a way that the
phenyl ring was facing the heme center leading to their behavior as competitive inhibitors. On the
other hand, smaller derivatives with just alkyl substituents docked with the ethynyl group facing the
heme that could explain the time-dependent inhibition of CYP1A2 by these molecules.
The advent of hormone replacement therapies in early/late menopausal women has been
associated with a higher risk for breast cancer [60]. This has been attributed to the increased levels
of hormones that are known procarcinogens [24,61]. Estrogen is metabolized by CYP enzymes
(CYP1A1, CYP 1A2, CYP 1B1 and CYP 3A4) to its 2,3-dihydroxy and 3,4-dihydroxy forms. The
2,3-dihydroxy form is methylated to its non-carcinogenic form by cathecol-o-methyl transferase [62,63].
The 3,4-dihydroxy form is oxidized to its carcinogenic quinone form, which is a marker for human
breast tumors, by peroxidases [24,61]. Yamamoto et al. have performed docking studies of
17β-estradiol on CYP1A1, CYP1A2 and CYP1B1 using Surflex Dock and the docked complexes
were scored using an empirical scoring function based on the Hammerhead docking system [64]. They
looked for binding modes that positioned the A-ring of the molecule within 5.5 Å of the heme iron atom.
The binding mode of 17β-estradiol was identical for CYP1A1 and CYP1A2 and it differed from the
one for CYP1B1. The accommodation of the 18-methyl group in the binding pocket was the deciding
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factor in determining the binding orientations of 17β-estradiol in the active sites of CYP1A1, CYP1A2
and CYP1B1 enzymes. These studies clearly indicate that CYP1B1 preferably oxidizes the 4-position
while CYPs 1A1 and 1A2 prefer the 2-position. Docking studies of the keto form of estrogen, namely,
estrone on the CYP1A1, CYP1A2, CYP3A4 and CYP1B1 were performed by Olah et al. using AutoDock
Vina docking program [65]. Their results also indicated that the 2-position of estrone is primarily
hydroxylated by CYP1A1 and CYP1A2, whereas, CYP1B1 preferably hydroxylated the 4-position.
During the development of a new class of quinone and anthraquinone inhibitors for CYP 1A
enzymes, an ortho-methylaminoanthraquinone was found to be a time-dependent inhibitor of both
CYP1A1 and CYP1A2 enzymes [36]. Docking studies on CYP1A1 and CYP1A2 showed that the methyl
group was in close proximity to the heme, enabling the enzyme to oxidize the methyl group. Due to the
presence of an amino group at the ortho position, the authors proposed that the hydrogen abstraction
of the methyl group by an iron-oxo species would lead to the formation of a benzylic carbon radical
intermediate. To better understand the nature of this proposed mechanism, the authors explored
the inhibition characteristics of several polycyclic ortho-methylheteroarylamines [37]. Most of these
compounds inhibited both CYP1A1 and CYP1A2 enzymes, with the linear planar molecules showing
a marginal selectivity for CYP1A1. Four of these compounds showed time-dependent inhibition of
CYP1A1 and not CYP1A2. Docking studies showed that the linear planar shape of molecules resulted
in a better binding orientation in the active site of CYP1A1. Additionally, the molecules that had
the aromatic methyl group in close proximity to the heme iron showed time-dependent inhibition of
CYP1A1 with a mechanism similar to that of furafylline. Furafylline is a caffeine analog that selectively
inhibits CYP1A2 (IC50 = 0.07 µM) over CYP1A1 (IC50 > 500 µM) and other CYP enzymes [66,67].
Furthermore , furafylline was found to be a mechanism-based inhibitor of CYP1A2 with a Ki of 23 µM
and a Kinact of 0.87 min−1. Docking studies have revealed that the furan ring interacts with Phe125
of CYP1A2 resulting in the 8-methyl group being directed towards the heme iron [68]. Isotope effects
have clearly shown that the initiating step is the abstraction of a hydrogen from the C-8 methyl group of
furafylline by P4501A2 [66]. It has been suggested that the loss of P450 observable spectroscopy could
be the result of the formation of a reactive intermediate that may alkylate the heme prosthetic group
or an amino acid in close proximity. Glycine scanning studies of the enzyme-ligand complexes for the
compounds that were selective CYP1A1 time-dependent inhibitors showed that the ligands were making
strong π-π interaction with the Phe123, Phe224 and Phe258 with a sandwich configuration contributing
to the stabilization of the protein-ligand complexes [37]. π-π interaction of the ligand with Phe123
was the largest contributor for the complex stability. A similar glycine scanning study was performed
for a set of carbazole analogs that are selective inhibitors of CYP1A2. Four residues in the active site
contributed the most to the stability of the protein-ligand complex- Glu225, Phe226, Phe260 and Leu497.
The ligand π-π interactions with the Phe residues were the strongest contributors for the stability of the
complex. Additionally, Leu497 formed strong aromatic-aliphatic interactions by the positioning of this
residue above a ligand aromatic ring. While Glu225 did not make any hydrogen bonds with the ligand,
nonspecific aliphatic interactions contributed to the binding stability of the ligands.
Nitropolycyclic aromatic hydrocarbons (nitro-PAHs) are formed in the environment by the
reaction of PAHs with nitrogen oxides in the atmosphere. The nitro-PAHs are metabolically activated
by enzymes such as NADPH:quinone oxidoreductase (NQO1), NADPH:CYP oxidoreductase (POR),
and CYP enzymes 1A1 and 1A2. Using theoretical and experimental approaches Stiborova et al. have
shown that CYP1A1 and CYP1A2 efficiently activate the nitro-PAHs under anaerobic conditions to
mutagens that bind to the DNA to form DNA adducts [69]. 3-Nitrobenzanthrone (3-NBA), found
in diesel exhaust, is reductively activated to 3-aminobenzanthrone (3-ABA) by both NQO1 and
CYP1A1/2 enzymes. The reductive activation of 3-NBA and the oxidative activation of 3-ABA, lead to
the common intermediate N-hydroxy-3-nitrobenzanthrone (N-OH-3-ABA). To understand the reaction
mechanisms of 3-NBA reduction by CYP1A1/2 enzymes, the authors performed docking studies
using molecular modeling tools. A step-wise reduction mechanism (e−, H+, e−, H+) was proposed
for the reduction of 3-NBA by CYP1A1/2. The binding orientation of 3-NBA to the CYP enzymes
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which allowed fast electron flow from the porphyrin ring of the heme cofactor was studied (Figure 8).
This binding orientation was identical for both the CYP1A1 and CYP1A2 enzymes, wherein the nitro
group of 3-NBA was in close proximity to the excellent proton donor threonine residues 497 and 498
in CYP1A1 and CYP1A2 which enables reduction of the compound. The same compound showed
a different orientation in the active site of CYP1B1 in which the nitro group was oriented close to
amidic side chains of Asn228 and Gln332 that are inferior proton donors. The estimated binding free
energy for CYCP1A1 and CYP1A2 was −8.04 kcal/mol and −8.02 kcal/mol, respectively, which was
much higher than the one for CYP1B1 (−7.73 kcal/mol).
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Figure 8. Adapted from reference [56]. The most favorable binding orientations of 3-NBA docked
into the active site of CYP1A1 (A), 1A2 (B) and 1B1 (C). Hydrogen bonds between 3-NBA and the
amino acid residues in active site residues are rendered as dashed black lines. 3-NBA (pink), heme
(grey) and side chains of important amino acid residues (cyan) are rendered as bold sticks; iron ions as
orange spheres.
Aristolic acid I (A I) is a plant alkaloid procarcinogen etabolize by several cytochrome P450
enzymes, with CYP1A2 nd CYP1A1 being the major enzymes i volved in the O-demethylation of
aristolic acid in o the carcinogen 8-hydroxyaristolic acid I. Docking studies by Stiborova et al. [15]
reve ed that th ing fr e energy of AAI to CYP1A1 was −7.0 kcal/mol and to CYP1A2 was
−7.7 kcal/mol. These b n ing free energies were far g ater th n the ones for YP2C9 and CYP3A4
(−5.3 and −6.0 kcal/mol). This data clearly showed the preferred oxidation of AAI by CYP1A2
followed by CYP1A1 when compared to other P450 enzymes.
An integrated approach has been employed by Kesharwani et al. that applied molecular
docking and molecular dynamic simulations of the protein-ligand complexes of a wide variety
of P450 1A substrates [32]. Five classes of substrates were chosen based on their ability to be
(i) preferably metabolized by CYP1A1 (5-aminoflavone and 5F-203); (ii) metabolized at different
rates and percentages by CYP1A1/1A2/1B1 (17-betaestradiol and theophylline); (iii) metabolized
at same rates and percentages by CYP1A1/1A2/1B1 (melatonin); (iv) preferably metabolized by
CYP1A2 (clozapine and lidocaine); and (v) metabolized by all three enzymes CYP1A1/1A2/1B1 with
specificity to CYP1A1 (debrisoquine) (Figure 9). Docking studies were performed using Glide, and the
docked poses were ranked based on their binding orientation and distance from the heme to the site of
metabolism on the ligand. Further MD simulation analysis of the docked complexes and calculation of
the Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) binding free energies provided
atomic level information on the protein-ligand interactions. The docking studies were in accordance
with the in-vitro results trend in terms of the enzyme t t the ligand was most active against. The MD
simulations and the MM-PBSA calculations m tched up well for 5 ami oflavone, 17-betaestradiol,
debrisoquine, nd theophylline. Khan et al. performed docki g studies using AutoDock Tools 4.0
followed by MD simulations of the protein-ligand complexes for several e vironme tal polycyclic
aromatic procarcinogens such as dib nzo[a,l]pyrene (DBP), 7,12-dimethyl-benz[a]anthracene (DMBA),
2-amino-1-methyl-6-phenyli idazo[4,5-b]pyridine (PhIP) and benzo[a]-pyrene (BP) on several CYP
enzymes including CYP1A1 and CYP1A2 (Figure 9). CYP1A1 was found to be the predominant enzyme
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that metabolized BP, DMBA and PhIP with high binding energies of−11.50 kcal/mol,−11.24 kcal/mol
and −9.43 kcal/mol, respectively. The in-silico findings for PhIP was different from the published
experimental data, and this variation was attributed to the variation in the pKa values of certain
ionizable residues in the binding groove of the CYP enzymes [70]. Qiu et al. studied the molecular
interactions of 12 ginger components (including gingerols, shogaols, gingerdiones, and isogingerols,
etc.) that are actively metabolized by the CYP enzymes 1A2, 2C9, 2C19, 2D6 and 3A4. Ginger
is one of the most widely used herbal dietary ingredients and is known to have several important
pharmacological activities including the maintenance of the levels of lipid, blood glucose, thromboxane
B and prostaglandin E2; inhibition of cytokines and chemokines; and blockage of Ca2+ channel. Nearly
128 compounds have been isolated from ginger with gingerols, phenylpropanoids and sesquiterpenes
being the most pungent of them. Shogoal and gingerol are partially responsible for the antiemetic
activity. Docking studies have shown that CYP2D6 plays a major role in the metabolism of ginger
components while CYP1A2, CYP2C9, CYP3A3 and CYP2C19 also metabolize ginger components, but
to a lower extent. The Discovery Studio 3.1 CDOCKER was used for performing the docking studies.
The CDOCKER interaction energies ranged from 23.0 to 63.1 kcal/mol. Three residues of CYP1A2
(Gly316, Phe226, and Phe260) interacted with the ginger compounds. 10-Gingerol made a hydrogen
bonding interaction with Gly316 (CDOCKER interaction energy of 61.3568 kcal/mol) and 4 ginger
compounds (6-shogaol, 8-shogaol, 6-gingerdione and methyl-6-isogingerol) made 1 to 2 π-π stacking
interactions with Phe226 and/or Phe260 (CDOCKER interaction energies of 55.9354, 58.6712, 59.0853
and 51.232 kcal/mol, respectively). The CDOCKER interaction energies from the docking studies
indicated that hydrogen bonding plays a greater role in the affinity of these compounds to the binding
site of CYP1A2 than the π-π stacking [71].
Molecules 2017, 22, 1143  13 of 18 
 
different from the published experimental data, and this variation was attributed to the variation in 
the pKa values of certain ionizable residues in the binding groove of the CYP enzymes [70]. Qiu et al. 
studied the molecular interactions of 12 ginger components (including gingerols, shogaols, 
gingerdiones, and isogingerols, etc.) that are actively metabolized by the CYP enzymes 1A2, 2C9, 
2C19, 2D6 and 3A4. Ginger is one of the most widely used herbal dietary ingredients and is known 
to have several important pharmacological activities including the maintenance of the levels of lipid, 
blood glucose, thromboxane B and prostaglandin E2; inhibition of cytokines and chemokines; and 
blockage of Ca2+ channel. Nearly 128 compounds have been isolated from ginger with gingerols, 
phenylpropanoids and sesquiterpenes being the most pungent of them. Shogoal and gingerol are 
partially responsible for the antiemetic activity. Docking studies have shown that CYP2D6 plays a 
major role in the metabolism of ginger components while CYP1A2, CYP2C9, CYP3A3 and CYP2C19 
also metabolize ginger components, but to a lower extent. The Discovery Studio 3.1 CDOCKER was 
used for performing the docking studies. The CDOCKER interaction energies ranged from 23.0 to 
63.1 kcal/mol. Three residues of CYP1A2 (Gly316, Phe226, and Phe260) interacted with the ginger 
compounds. 10-Gingerol made a hydrogen bonding interaction with Gly316 (CDOCKER interaction 
energy of 61.3568 kcal/mol) and 4 ginger compounds (6-shogaol, 8-shogaol, 6-gingerdione and 
methyl-6-isogingerol) made 1 to 2 π-π stacking interactions with Phe226 and/or Phe260 (CDOCKER 
interaction energies of 55.9354, 58.6712, 59.0853 and 51.232 kcal/mol, respectively). The CDOCKER 
interaction energies from the docking studies indicated that hydrogen bonding plays a greater role 
in the affinity of these compounds to the binding site of CYP1A2 than the π-π stacking [71]. 
 
Figure 9. Structures of compounds studied by Kesharwani et al. [32] and Kahn et al. [57]. 
8. Photo Affinity Ligands (PALs) as Binding Site Probes 
In 1962, Singh and Westheimer were the first who applied PALs to biochemical studies. PALs 
do not require any enzymatic activity to be utilized as active site probe. These ligands are in general 
very sensitive to the light and mostly are found to be stable in dark [72]. They can bind the chemically 
inert compound to the protein active site in the dark reversibly, and then irradiate the sample to 
Figure 9. Structures of compounds studied by Kesharwani et al. [32] and Kahn et al. [57].
Molecules 2017, 22, 1143 14 of 19
8. Photo Affinity Ligands (PALs) as Binding Site Probes
In 1962, Singh and Westheimer were the first who applied PALs to biochemical studies. PALs do
not require any enzymatic activity to be utilized as active site probe. These ligands are in general very
sensitive to the light and mostly are found to be stable in dark [72]. They can bind the chemically inert
compound to the protein active site in the dark reversibly, and then irradiate the sample to produce the
reactive moiety. In case of PALs with aliphatic side chains, the aliphatic group can be covalently labeled
via photogeneration of a radical from the parent ligand. They do not always require nucleophilic
amino acid residues to be in close proximity. The first example was reported by Swanson and Dus
where they used tritiated 1-(4-azidophenyl)imidazole (Figure 10) [73] to successfully and quantitatively
label P450cam. The compound was used as a general probe as N-phenylimidazole binds with high
affinity to several P450 enzymes. The earliest success in photolabeling of P450 1A1 came in 1992 with
the use of compounds having azo moiety on warfarin (Figure 10) [74]. The authors reported that they
prepared different isomers of warfarin with azide group which was placed at different positions. In the
same year Guengerich and his coworkers reported that they have successfully demonstrated the use
of 4-azidobiphenyl (Figure 10) as a PAL of rat cytochrome P450 1A2 [75] and the covalent binding of
the ligand following photolysis was shown in such a way that was PAL concentration-dependent and
which increased with irradiation time.
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In 1996, Strobel and coworkers first reported the use of bifunctional crosslinking PAL [76–78].
They used a benzphetamine anal g having two azido groups which were placed at opposite ends.
Strobel and coworkers used radiolabeled p-azidocumene (Figur 10) to identify the critical ami o
aci residue of P450 1A1 involved in binding of cumene hydroperoxide [76]. The experiments and
studies performed by these and many other research groups have provided crucial data, which help in
understanding the binding site of the CYP enzymes.
9. Conclusions
Computational molecular modeling studies have shed important insights into the binding of
substrates to CYP1A1 and CYP1A2 enzymes. These studies have led to several i portant findings
about the structural features imparting specificity and potency toward these enzymes. Ligand-based
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studies such as QSAR studies and structural meta-analysis studies have clearly shown that planar
molecules are the best substrates for these enzymes. CYP1A1 shows a preference for linear planar
molecules while CYP1A2 prefers triangular planar molecules. Protein-based studies have included
docking studies and molecular dynamic simulations of protein-ligand docked complexes. The docking
studies have shown the importance of edge-to-face and offset stacked π-π stacking of the ligand
aromatic rings with the various Phe residues in the binding site of the CYP1A1 and CYP1A2 enzymes.
These π-π stacking interactions were found to be the strongest contributors to the stable binding of
ligands to CYP1A2. Docking studies have also shown that the optimum distance between the heme
iron and the position of oxidation on the substrate should be between 4.0 Å and 7.0 Å. The positioning
of polar substituents on the ligands in close proximity to polar residues in the binding site also
favors good binding free energies for the complexes. The insights obtained by these studies will help
researchers to design and develop highly specific inhibitors of CYP1A1 and CYP1A2 enzymes.
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